Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics

Several different factors have been associated with an increased risk of asthma exacerbations, such as sex, age, obesity, age at asthma onset, and asthma control; additionally, prior exacerbation history is a significant independent predictor of future exacerbation risk for patients with asthma [1]. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflict of interest: M. E. Weschler reported personal fees from AstraZeneca, Boehringer Ingelheim, Equillium, Gala Therapeutics, Genentech, Genzyme, Mylan, Novartis, Pulmatrix, Regeneron Pharmaceuticals Inc., resTORbio, Sentien Biotechnologies, and Teva; and grants and personal fees from GSK and Sanofi. Conflict of interest: L. Rogers reported research support from American Lung Association, NIH, and Sanofi; consultancy for AstraZeneca, Genentech, Novartis, and Sanofi; and payments for organizing educational events from AstraZeneca and Genentech. Conflict of interest: G. W. Canonica reported speaker fees from ALK, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HAL Allergy, Menarini, Mundipharma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, Stallergenes Greer, and Uriach; and advisory board membership for ALK, AstraZeneca, Boehringer Ingelheim, GSK, HAL Allergy, Menarini, Mundipharma, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, Stallergenes Greer, and Uriach. Conflict of interest: A. Bourdin reported non-financial support during the conduct of the study from GSK; other from Acceleron Pharma, Actelion, Galapagos, Merck Sharp & Dohme, Nuvaira, Pulmonx, United Therapeutics, and Vertex Pharmaceuticals; grants and personal fees from Boehringer Ingelheim; and personal fees from AstraZeneca, Chiesi, GSK, Regeneron Pharmaceuticals Inc., and Sanofi. Conflict of interest: A. Altincatal, M. Hardin, P. J. Rowe, and J. A. Jacob-Nara are employees of Sanofi, and may hold stock and/or stock options in the company. Conflict of interest: X. Soler and Y. Deniz are employees and shareholders of Regeneron Pharmaceuticals Inc. Conflict of interest: H. Sacks. is an employee of Regeneron Pharmaceuticals Inc., and a shareholder in Optinose.